lixisenatide vs Utreglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
lixisenatide · Adlyxin / Lyxumia
Marketed by Sanofi and partners
NCT00707031 · Phase 3 · completed
The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)
Result source: NCT00707031
Utreglutide
Developed by Sun Pharmaceutical Industries
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07282743 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | lixisenatide | Utreglutide |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.6 vs placeboNCT0179870619 other results
| —Not reported |
| Body weight, change (kg) | -0.6 vs 1.0vs Insulin GlulisineNCT0176855917 other results
| —Not reported |
| HbA1c below 7% | 53% vs 38.8%+14.2 vs placeboNCT0116977910 other results
| —Not reported |
| Fasting plasma glucose, change | -0.3 vs 0.0−0.3 vs placeboNCT0179870617 other results
| —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- lixisenatide
- -0.6% vs 0.1%−0.6 vs placeboNCT01798706
19 other results
- -0.8% vs -0.5% NCT01169779
- -0.7% vs -0.4% NCT00975286
- -0.9% vs -0.3% NCT00763815
- -0.7% vs -0.4% NCT00715624
- -0.8% vs -0.1% NCT00713830
- -0.8% vs -0.4% NCT00763451
- -0.9% vs -0.4% NCT00763451
- -0.8% vs 0.1% NCT00866658
- -1.1% vs -0.6% NCT02058160
- -1.6% vs -1.3% NCT02058147
- -0.8% vs -1.3% NCT02058147
- -0.6% vs -0.8% NCT01768559
- -0.8% vs -1.0% NCT00707031
- -1.9% vs -1.7% NCT05413369
- -1.9% vs -1.7% NCT05413369
- -0.7% vs -0.7% NCT00976937
- -1.8% vs -1.6% NCT01476475
- -0.6% vs -0.7% NCT01596504
- -0.3% vs -0.5% NCT01175473
- Utreglutide
- —Not reported
Body weight, change (kg)
- lixisenatide
- -0.6 vs 1.0vs Insulin GlulisineNCT01768559
17 other results
- -1.5 vs -0.2 NCT01798706
- -1.5 vs -1.2 NCT01169779
- 0.3 vs 1.2 NCT00975286
- -0.2 vs 0.2 NCT00763815
- -1.8 vs -0.5 NCT00715624
- -1.8 vs -0.9 NCT00713830
- -2.7 vs -1.6 NCT00763451
- -2.6 vs -1.6 NCT00763451
- -0.4 vs 0.1 NCT00866658
- -0.7 vs 0.7 NCT02058160
- -0.3 vs 1.1 NCT02058147
- -2.3 vs 1.1 NCT02058147
- -3.0 vs -4.0 NCT00707031
- -0.3 vs 1.2 NCT05413369
- -2.5 vs -1.2 NCT00976937
- -1.0 vs 0.5 NCT01476475
- -1.6 vs -2.4 NCT01596504
- Utreglutide
- —Not reported
HbA1c below 7%
- lixisenatide
- 53% vs 38.8%+14.2 vs placeboNCT01169779
10 other results
- 56.3% vs 38.5% NCT00975286
- 52.3% vs 26.4% NCT00763815
- 28.3% vs 12% NCT00715624
- 36.4% vs 13.5% NCT00713830
- 42.1% vs 24.1% NCT00763451
- 47.4% vs 24.1% NCT00763451
- 35.6% vs 5.2% NCT00866658
- 48.5% vs 49.8% NCT00707031
- 72.5% vs 59.8% NCT05413369
- 40.7% vs 40% NCT00976937
- Utreglutide
- —Not reported
Fasting plasma glucose, change
- lixisenatide
- -0.3 vs 0.0−0.3 vs placeboNCT01798706
17 other results
- -0.7 vs -0.2 NCT01169779
- 0.3 vs 0.5 NCT00975286
- -1.2 vs -0.3 NCT00763815
- -0.6 vs -0.6 NCT00715624
- -1.0 vs -0.4 NCT00713830
- -0.6 vs 0.1 NCT00763451
- -0.5 vs 0.1 NCT00763451
- -0.4 vs 0.3 NCT00866658
- -0.3 vs -0.5 NCT02058160
- -3.5 vs -3.3 NCT02058147
- -1.5 vs -3.3 NCT02058147
- -0.2 vs -0.2 NCT01768559
- -1.2 vs -1.4 NCT00707031
- -3.2 vs -3.5 NCT05413369
- -0.5 vs -0.7 NCT00976937
- -3.4 vs -3.5 NCT01476475
- 0.1 vs 0.1 NCT01596504
- Utreglutide
- —Not reported
3-point MACE (% with event)
- lixisenatide
- —Not reported
- Utreglutide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Utreglutide: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. lixisenatide: 4 of 4 rows · Utreglutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | lixisenatide |
|---|---|
| Dropout rate | 32.5%a NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.2%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 8.3%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 3.5% NCT01147250 · Phase 3 11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 5.8% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 10.5%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 12.4%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 11.9% NCT01798706 · Phase 3 · registry result, not featured evidence 10.1% NCT01768559 · Phase 3 · registry result, not featured evidence 10.6%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 16%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 8.7% NCT01169779 · Phase 3 · registry result, not featured evidence 13% NCT00975286 · Phase 3 · registry result, not featured evidence 26% NCT00763815 · Phase 3 · registry result, not featured evidence 27.5%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 22.4%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 10.1% NCT00976937 · Phase 3 · registry result, not featured evidence 35.3% NCT00715624 · Phase 3 · registry result, not featured evidence 30.9% NCT00713830 · Phase 3 · registry result, not featured evidence 18.6%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 24.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 25%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 39.4%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 13.6% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 4.2%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 6.8% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 14.1%a NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results2.5%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 4.2%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 — NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.3% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 3.9%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence — NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 8.5% NCT01798706 · Phase 3 · registry result, not featured evidence 5% NCT01768559 · Phase 3 · registry result, not featured evidence 4.9%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 4.4%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 5.6% NCT01169779 · Phase 3 · registry result, not featured evidence 8.5% NCT00975286 · Phase 3 · registry result, not featured evidence 9% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 2.5% NCT00976937 · Phase 3 · registry result, not featured evidence 11.2% NCT00715624 · Phase 3 · registry result, not featured evidence 12.4% NCT00713830 · Phase 3 · registry result, not featured evidence 8.7%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 11.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 13.9%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 21.2%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 9.1% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 2.1%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 3.7% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 8.2%a NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results0%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 0.8%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 20.6% NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 5.2% NCT05413369 · Phase 3 · registry result, not featured evidence 3.9%Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence 10.2%Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination 5.5% NCT02058160 · Phase 3 · registry result, not featured evidence 3.8%Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 3.9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 4.5% NCT01798706 · Phase 3 · registry result, not featured evidence 3.7% NCT01768559 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 1.5% NCT01169779 · Phase 3 · registry result, not featured evidence 7.6% NCT00975286 · Phase 3 · registry result, not featured evidence 7.7% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 1.9% NCT00976937 · Phase 3 · registry result, not featured evidence 14% NCT00715624 · Phase 3 · registry result, not featured evidence 10.1% NCT00713830 · Phase 3 · registry result, not featured evidence —Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 13%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 9.9%Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 2.8%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.1%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.5% NCT00866658 · Phase 3 · registry result, not featured evidence 2.1%20 µg NCT01596504 · Phase 2 · registry result, not featured evidence —20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 5.6% NCT01476475 · Phase 2 · registry result, not featured evidence 0% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 28.6% nasopharyngitis 15.4% diarrhoea 15.1% NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 31 more resultsnausea 20.2% (placebo 3.3%) headache 7.6% (placebo 8.2%) vomiting 6.7% (placebo 0%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 24.2% (placebo 3.3%) headache 8.3% (placebo 8.2%) dizziness 7.5% (placebo 3.3%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 21.7% (placebo 5.9%) hypoglycaemia 20.1% (placebo 18.3%) dizziness 8.5% (placebo 6.3%) NCT01147250 · Phase 3 hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 17.2% covid-19 13.4% nausea 12.1% NCT05413369 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.8% nausea 8.6% diarrhoea 5.5% NCT02787551 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% nausea 9.2% diarrhoea 7.3% NCT02787551 · Phase 3 · registry result, not featured evidence mild asymptomatic hypoglycaemia 33.3% hypercholesterolaemia 22.2% mild gastrointestinal complaints 22.2% NCT02168491 · Phase 3 · registry result, not featured evidence · combination nausea 10.4% nasopharyngitis 8.8% headache 5.8% NCT02058160 · Phase 3 · registry result, not featured evidence nausea 9.6% diarrhoea 9% upper respiratory tract infection 7% NCT02058147 · Phase 3 · registry result, not featured evidence nausea 25% (placebo 7.5%) hypoglycaemia 17% (placebo 10.3%) diarrhoea 10.8% (placebo 7.5%) NCT01798706 · Phase 3 · registry result, not featured evidence hypoglycaemia 35.9% nausea 25.2% blood glucose decreased 20.1% NCT01768559 · Phase 3 · registry result, not featured evidence nausea 15.5% headache 7.1% nasopharyngitis 7.1% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 14.7% nasopharyngitis 9.8% hypoglycaemia 6.7% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 16.3% (placebo 2.6%) hypoglycaemia 9.2% (placebo 4.6%) dizziness 8.7% (placebo 4.1%) NCT01169779 · Phase 3 · registry result, not featured evidence hypoglycaemia 27.4% (placebo 19.3%) nausea 27.4% (placebo 4.9%) headache 9.9% (placebo 3.6%) NCT00975286 · Phase 3 · registry result, not featured evidence nausea 26% (placebo 13.7%) nasopharyngitis 16.4% (placebo 14.9%) headache 13.3% (placebo 11.8%) NCT00763815 · Phase 3 · registry result, not featured evidence nausea 24.7% (placebo 10.6%) headache 16.5% (placebo 23.5%) vomiting 15.7% (placebo 3.5%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 25.1% (placebo 10.6%) headache 19.2% (placebo 23.5%) diarrhoea 15.3% (placebo 11.8%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 17.7% headache 12.7% diarrhoea 8.9% NCT00976937 · Phase 3 · registry result, not featured evidence hypoglycaemia 42.1% (placebo 40.7%) nausea 29.3% (placebo 9.6%) headache 12.5% (placebo 10.2%) NCT00715624 · Phase 3 · registry result, not featured evidence nausea 28% (placebo 8.8%) hypoglycaemia 24.4% (placebo 19.3%) nasopharyngitis 15.9% (placebo 20.4%) NCT00713830 · Phase 3 · registry result, not featured evidence nausea 37.9% (placebo 8.1%) vomiting 18% (placebo 0.6%) diarrhoea 14.9% (placebo 13.1%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 29.2% (placebo 8.1%) vomiting 13% (placebo 0.6%) headache 12.4% (placebo 12.5%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 50% nasopharyngitis 36.1% decreased appetite 19.4% NCT00905255 · Phase 3 · registry result, not featured evidence nausea 36.4% nasopharyngitis 27.3% decreased appetite 18.2% NCT00905255 · Phase 3 · registry result, not featured evidence hypoglycaemia 43.5% (placebo 23.6%) nausea 39.6% (placebo 4.5%) vomiting 18.2% (placebo 1.9%) NCT00866658 · Phase 3 · registry result, not featured evidence 20 µg decreased appetite 18.8% nausea 18.8% nasopharyngitis 12.5% NCT01596504 · Phase 2 · registry result, not featured evidence nausea 7.5% nasopharyngitis 5.6% headache 5% NCT01476475 · Phase 2 · registry result, not featured evidence nausea 22.1% decreased appetite 18.2% headache 11.7% NCT01175473 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 32 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
lixisenatide
show 19 more results
show 17 more results
show 17 more results
show 10 more results
show 9 more results
show 15 more results
show 8 more results
show 6 more results
show 1 more result
show 6 more results
show 6 more results
show 3 more results
+ 73 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lixisenatide's landscape · Utreglutide's landscape